ArticleJournal of enzyme inhibition and medicinal chemistry2022
Structure-activity relationship studies for inhibitors for vancomycin-resistant
Open access · goldAbstract read
In one paragraph
Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Structure-Activity Relationship Studies for 1,3,4-Thiadiazole-Based Bacterial Carbonic Anhydrase Inhibitors withJournal of medicinal chemistry · 2026Article
- Bacterial β-carbonic anhydrases: a six-step prioritization framework for antibacterial target validation.Archives of microbiology · 2026Review
- Bacterial Carbonic Anhydrase Inhibitor CAI0019 Demonstrates Efficacy inACS infectious diseases · 2026Article
- Antibiofilm and antibacterial activity of maslinic acid against Vancomycin-Resistant Enterococci (VRE).PloS one · 2026Article
- Future Directions in Biotechnological and Pharmacological Applications of CAIs.Sub-cellular biochemistry · 2026Review
- Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci.Scientific reports · 2025Article
- Hit-to-Lead Optimization of Acetazolamide-Based Bacterial Carbonic Anhydrase Inhibitors with Efficacy In Vivo for Treatment of Vancomycin-Resistant Enterococci Septicemia.Journal of medicinal chemistry · 2025Article
- Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant enterococci.European journal of medicinal chemistry · 2025Article
- Acetazolamide-Loaded Nanoparticle Based on Modified Hyaluronic Acid as Delivery System to Target Carbonic Anhydrases inInternational journal of molecular sciences · 2025Article
- Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-ResistantJournal of medicinal chemistry · 2024Article
- Inhibition of pathogenic bacterial carbonic anhydrases by monothiocarbamates.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Inhibition studies with simple and complex (in)organic anions of the γ-carbonic anhydrase fromJournal of enzyme inhibition and medicinal chemistry · 2023Article
- 4-Cyanamidobenzenesulfonamide derivatives: a novel class of human and bacterial carbonic anhydrase inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Sulphonamide inhibition studies of the β-carbonic anhydrase GsaCAβ present in the salmon platyhelminth parasiteJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Dentine biomodification by sulphonamides pre-treatment: bond strength, proteolytic inhibition, and antimicrobial activity.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Evaluation of 1,3,4-Thiadiazole Carbonic Anhydrase Inhibitors for Gut Decolonization of Vancomycin-Resistant Enterococci.ACS medicinal chemistry letters · 2023Article
- Carbonic Anhydrase Inhibitors as Novel Antibacterials in the Era of Antibiotic Resistance: Where Are We Now?Antibiotics (Basel, Switzerland) · 2023Review
- Click chemistry approaches for developing carbonic anhydrase inhibitors and their applications.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- Activation studies with amino acids and amines of a β-carbonic anhydrase fromJournal of enzyme inhibition and medicinal chemistry · 2022Article
- The gram-negative bacteriumJournal of enzyme inhibition and medicinal chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Weiwei AnDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.
Katrina J HollyDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.ORCID 0000-0002-5193-4503
Alessio NocentiniDepartment of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Italy.ORCID 0000-0003-3342-702X
Ryan D ImhoffDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.ORCID 0000-0002-8510-8437
Chad S HewittDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.
Nader S AbutalebDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Xufeng CaoDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.
Mohamed N SeleemDepartment of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Italy.ORCID 0000-0003-0939-0458
Claudiu T SupuranDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.ORCID 0000-0003-4262-0323
Daniel P FlahertyDepartment of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN, USA.ORCID 0000-0002-8305-0606
Purdue University West Lafayette · USVirginia–Maryland College of Veterinary Medicine · USNational Center for Emerging and Zoonotic Infectious Diseases · USPurdue Pharma (Canada) · CAUniversity of Florence · IT
Funding
Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococciR01AI148523 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Daniel Patrick Flaherty, Mohamed Seleem · 2019 to 2026
$4.2MNIAID NIH HHS R01 AI148523
Abstract
Vancomycin-resistant enterococci (VRE), consisting of pathogenic
Indexed as
Carbonic AnhydrasesGram-Positive Bacterial InfectionsVancomycin-Resistant EnterococciAcetazolamideAnti-Bacterial AgentsCarbonic Anhydrase InhibitorsEnterococcus faecalisHumansMicrobial Sensitivity TestsStructure-Activity RelationshipVancomycinAcetazolamideAnti-Bacterial AgentsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesVancomycinantibioticsCarbonic anhydrase inhibitorsdrug repurposingvancomycin-resistant Enterococcus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.